421 related articles for article (PubMed ID: 15197637)
1. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
Uys A; Rapoport BL; Anderson R
Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
[TBL] [Abstract][Full Text] [Related]
2. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
[TBL] [Abstract][Full Text] [Related]
3. Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients.
de Souza Viana L; Serufo JC; da Costa Rocha MO; Costa RN; Duarte RC
Support Care Cancer; 2008 Jul; 16(7):841-6. PubMed ID: 17960431
[TBL] [Abstract][Full Text] [Related]
4. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
Baskaran ND; Gan GG; Adeeba K
Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
Ahn S; Rice TW; Yeung SJ; Cooksley T
Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
[TBL] [Abstract][Full Text] [Related]
6. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
[TBL] [Abstract][Full Text] [Related]
7. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.
Klastersky J; Paesmans M; Rubenstein EB; Boyer M; Elting L; Feld R; Gallagher J; Herrstedt J; Rapoport B; Rolston K; Talcott J
J Clin Oncol; 2000 Aug; 18(16):3038-51. PubMed ID: 10944139
[TBL] [Abstract][Full Text] [Related]
8. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.
Klastersky J; Paesmans M; Georgala A; Muanza F; Plehiers B; Dubreucq L; Lalami Y; Aoun M; Barette M
J Clin Oncol; 2006 Sep; 24(25):4129-34. PubMed ID: 16943529
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis.
Zheng B; Toarta C; Cheng W; Taljaard M; Reaume N; Perry JJ
Crit Rev Oncol Hematol; 2020 May; 149():102922. PubMed ID: 32244162
[TBL] [Abstract][Full Text] [Related]
10. Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network.
Hui EP; Leung LK; Poon TC; Mo F; Chan VT; Ma AT; Poon A; Hui EK; Mak SS; Lai M; Lei KI; Ma BB; Mok TS; Yeo W; Zee BC; Chan AT
Support Care Cancer; 2011 Oct; 19(10):1625-35. PubMed ID: 20820815
[TBL] [Abstract][Full Text] [Related]
11. Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: is risk stratification useful?
Gunderson CC; Farrell R; Dinh BC; Thomas ED; Vesely SK; Lauer JK; Kao L; Chopra S; McMeekin DS; Moore KN
Gynecol Oncol; 2013 Sep; 130(3):411-5. PubMed ID: 23791827
[TBL] [Abstract][Full Text] [Related]
12. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10.
Uys A; Rapoport BL; Fickl H; Meyer PW; Anderson R
Eur J Cancer Care (Engl); 2007 Nov; 16(6):475-83. PubMed ID: 17944761
[TBL] [Abstract][Full Text] [Related]
13. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.
Coyne CJ; Le V; Brennan JJ; Castillo EM; Shatsky RA; Ferran K; Brodine S; Vilke GM
Ann Emerg Med; 2017 Jun; 69(6):755-764. PubMed ID: 28041827
[TBL] [Abstract][Full Text] [Related]
14. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies.
Cherif H; Johansson E; Björkholm M; Kalin M
Haematologica; 2006 Feb; 91(2):215-22. PubMed ID: 16461306
[TBL] [Abstract][Full Text] [Related]
15. Utility of the Multinational Association for Supportive Care in Cancer (MASCC) Risk Index Score as a Criterion for Nonadmission in Febrile Neutropenic Patients with Solid Tumors.
Bitar RA
Perm J; 2015; 19(3):37-47. PubMed ID: 26176568
[TBL] [Abstract][Full Text] [Related]
16. [Prognosis prediction of febrile neutropenia by MASCC score: A retrospective study].
Cervetti L; Vallard A; Le Moulec S; Espenel S; Falk AT; Ben Mrad M; Guy JB; Diao P; Méry B; Langrand-Escure J; Ferrand FR; Rivoirard R; Ceccaldi B; Védrine L; Magné N; Chargari C
Bull Cancer; 2016 Jun; 103(6):561-70. PubMed ID: 27181759
[TBL] [Abstract][Full Text] [Related]
17. Validation of MASCC Score for Risk Stratification in Patients of Hematological Disorders with Febrile Neutropenia.
Taj M; Nadeem M; Maqsood S; Shah T; Farzana T; Shamsi TS
Indian J Hematol Blood Transfus; 2017 Sep; 33(3):355-360. PubMed ID: 28824237
[TBL] [Abstract][Full Text] [Related]
18. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.
Carmona-Bayonas A; Jiménez-Fonseca P; Virizuela Echaburu J; Antonio M; Font C; Biosca M; Ramchandani A; Martínez J; Hernando Cubero J; Espinosa J; Martínez de Castro E; Ghanem I; Beato C; Blasco A; Garrido M; Bonilla Y; Mondéjar R; Arcusa Lanza MÁ; Aragón Manrique I; Manzano A; Sevillano E; Castañón E; Cardona M; Gallardo Martín E; Pérez Armillas Q; Sánchez Lasheras F; Ayala de la Peña F
J Clin Oncol; 2015 Feb; 33(5):465-71. PubMed ID: 25559804
[TBL] [Abstract][Full Text] [Related]
19. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia.
Ahn S; Lee YS; Lim KS; Lee JL
Support Care Cancer; 2013 Aug; 21(8):2303-8. PubMed ID: 23519568
[TBL] [Abstract][Full Text] [Related]
20. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?
Paesmans M; Klastersky J; Maertens J; Georgala A; Muanza F; Aoun M; Ferrant A; Rapoport B; Rolston K; Ameye L
Support Care Cancer; 2011 Jul; 19(7):1001-8. PubMed ID: 20596732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
